Clinical Trials Logo

Clinical Trial Summary

Allergic rhinitis (AR) is a global health problem affecting approximately 10% to 40% of the population worldwide, with an increasing trend. It significantly impacts health and quality of life. Current treatments for AR include allergen avoidance, symptom-relieving medications, anti-inflammatory therapy, and allergen-specific immunotherapy. However, many patients still experience uncontrolled symptoms despite these approaches, either as monotherapy or in combination, along with medication side effects such as drowsiness, dry eyes, nasal mucosal damage, and immunosuppression. Auricular acupressure therapy (AAT) utilizes ear acupoints by applying pressure with ear seeds. The neurobiological mechanisms of AAT on the human body have gained increasing attention in clinical and experimental studies, involving anti-inflammatory, antioxidant, and immunomodulatory effects. Its efficacy has been recognized, becoming a potential alternative therapy for various conditions such as sleep disorders, obesity, and chronic pain. Previous clinical studies have reported the efficacy and safety of AAT in treating AR. However, the primary outcomes of these studies remain inconsistent and lack specific criteria for evaluating AR treatment efficacy. This study aims to investigate the efficacy and safety of AAT in treating AR based on the ARIA guideline 2019 treatment efficacy criteria. It will provide a basis for applying AAT as a complementary approach in the multimodal treatment of AR.


Clinical Trial Description

Patients with allergic rhinitis who have typical symptoms such as nasal itching, runny nose, sneezing, nasal congestion, and are indicated for corticosteroid nasal spray according to the ARIA 2019 diagnostic and treatment guidelines will be registered for this study. They will then be randomly assigned to two groups: Intervention group (auricular acupressure therapy + fluticasone propionate nasal spray), and control group (sham auricular acupressure therapy + fluticasone propionate nasal spray). The allocation ratio for the two groups is 1:1. The intervention period for both groups is four weeks. Auricular acupressure therapy or sham acupressure therapy will be performed every week. Fluticasone propionate nasal spray will be used whenever symptoms occur. Patients will also be encouraged to adjust their lifestyle and living environment. Data on the severity of allergic rhinitis symptoms (including nasal itching, sneezing, runny nose, nasal congestion, eye symptoms, and headache), the Rhinitis Quality of Life Questionnaire (RQLQ), and side effects of auricular acupressure therapy will be recorded before the study and weekly for 4 weeks. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06323304
Study type Interventional
Source University of Medicine and Pharmacy at Ho Chi Minh City
Contact
Status Recruiting
Phase N/A
Start date March 13, 2024
Completion date June 2024

See also
  Status Clinical Trial Phase
Completed NCT00665977 - Effect of Heated Humidity With Thermosmartâ„¢ Compared to an Intranasal Steroid in Improving Compliance and Nasal Symptoms in Patients Using Continuous Positive Airway Pressure Phase 3
Completed NCT05843071 - PMCF Study to Evaluate Performance and Safety of "NASAL SPRAYS " Used to Relieve Nasal Congestion and Dryness N/A
Completed NCT00957996 - Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza Phase 3
Completed NCT00829634 - Steady State Kinetics of l-Methamphetamine and Validation of Sensitivity of Dose Estimation N/A
Completed NCT00662337 - Bioequivalence Between Two Oral Formulations of Diphenhydramine Hydrochloride Phase 1
Completed NCT05247333 - Implementation of a Minor Ailment Service in Community Pharmacy Practice N/A
Recruiting NCT05244148 - Two Seawater-based Formulations for Relief of Nasal Congestion in Paediatric Subjects N/A
Completed NCT05159271 - Efficacy and Safety of Azeol Nasal Spray Versus Placebo in the Treatment of Early Symptoms of Common Cold in Adults N/A
Completed NCT02113449 - Market Potential of Carbon Dioxide Nasal Spray Phase 2
Terminated NCT00958776 - A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza Phase 3
Completed NCT00648973 - To Determine if Diphenhydramine Works for Nasal Congestion at Two Different Doses Phase 4
Completed NCT03399721 - Investigation of Kinetic Oscillation Stimulation by the Chordate System S101 in the Treatment of Non Allergic Rhinitis N/A
Completed NCT01354418 - Bioequivalence of Single Dose Phenylephrine Extended Release Tablets and Phenylephrine HCl Immediate Release Tablets Dosed Every Four Hours (P08340)(COMPLETED) Phase 1
Completed NCT04797936 - BNO 1030 Extract (Imupret) in the Treatment of Mild Forms of COVID-19 Phase 4
Completed NCT03906968 - The Safety and Efficacy of a SinuSonic Intervention N/A
Completed NCT02100605 - Study on Hypertonic Saline Nasal Spray N/A
Withdrawn NCT04790487 - Chlorpheniramine Maleate Nasal Spray for Chronic Rhinitis Phase 2/Phase 3
Completed NCT01448057 - Evaluation of Efficacy and Safety of Tablets of Paracetamol, Dimethindene Maleate and Phenylephrine Hydrochloride in Reducing Symptoms of Common Cold and Flu Phase 3
Completed NCT01129765 - Home Usability of a Nasal Lavage System in Children N/A
Completed NCT04910139 - A User Study of the Soniflow System for Nasal Congestion Relief N/A